Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan

Novel therapeutic strategies are needed in the fight against pancreatic cancer. We have previously documented the chemopreventive effect of MDC-22 in preclinical models of pancreatic cancer. In the present work, we examined the therapeutic effects of MDC-22 in patient-derived tumor xenografts (PDTXs...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez Lanzi, Cecilia, Wei, Ran, Luo, Dingyuan, Mackenzie, Gerardo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717147/
https://www.ncbi.nlm.nih.gov/pubmed/34968866
http://dx.doi.org/10.1016/j.neo.2021.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717147/
https://www.ncbi.nlm.nih.gov/pubmed/34968866
http://dx.doi.org/10.1016/j.neo.2021.12.004

Ejemplares similares